Hetty Carraway, MD, and Eytan M. Stein, MD, discuss treatment options for patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia, and how to select the best treatment regimen based on patient and disease factors.
EP. 1: An Overview of Myelodysplastic Syndrome (MDS)
Eytan M. Stein, MD, provides an overview of myelodysplastic syndrome, including risk factors, symptoms, and diagnosis.
EP. 2: The Progression of Myelodysplastic Syndrome to Acute Myeloid Leukemia (AML)
Hetty Carraway, MD, describes how MDS differs from acute myeloid leukemia (AML), and the percentage of patients who progress to AML from MDS.
EP. 3: Risk Stratification for Patients with Myelodysplastic Syndrome
Dr Eytan M Stein breaks down how patients with MDS are risk-stratified, and how the clinical outcomes differ between risk groups.
EP. 4: Treatment Goals for Patients with Myelodysplastic Syndrome
Experts explain the treatment goals for patients with MDS, and discusses the role of molecular testing in patients with MDS.
EP. 5: Currently Available Treatment Options for Patients with Higher-Risk Myelodysplastic Syndrome
Dr Hetty Carraway reviews the available treatment options for patients with higher-risk MDS, and the biggest challenges of treatment.
EP. 6: Factors for Consideration when Choosing an Appropriate Treatment for Higher-Risk Myelodysplastic Syndrome
Eytan M. Stein, MD, outlines the biggest factors to consider when choosing a treatment for higher-risk MDS, including the differences in quality-of-life for patients.
EP. 7: The Role of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome
Hetty Carraway, MD, illustrates the role of allogenic stem cell transplant in MDS and the criteria used to determine a patient’s eligibility.
EP. 8: The Role of Hypomethylating Agents (HMAs) in Higher-Risk Myelodysplastic Syndrome Treatment
Key opinion leaders describe the role of hypomethylating agents in treating higher-risk MDS and the treatment options after HMA failure.
EP. 9: Magrolimab plus Azacitidine for Myelodysplastic Syndrome
Drs Stein and Carraway explain the rationale for a magrolimab and azacitidine combination treatment for patients with higher-risk MDS with supporting data from 2 clinical trials.
EP. 10: Potential Shift in the Treatment Paradigm of Higher-Risk MDS with Magrolimab
Dr Hetty Carraway muses on whether magrolimab plus azacitadine will be used as a standard treatment for higher-risk MDS in the future.
EP. 11: Treating Patients with Myelodysplastic Syndrome and IDH or TP53 Mutations
Eytan M. Stein, MD, discusses how to treat patients with MDS who have IDH or TP53 mutations, and whether there is a role for targeted therapy in this patient population.
EP. 12: Unmet Needs for Patients with Higher-Risk Myelodysplastic Syndrome
Dr Carraway highlights some of the most urgent unmet needs for patients with higher-risk MDS.
EP. 13: ENHANCE-2 Trial of Magrolimab plus Azacitidine in AML
Dr Stein explains clinical trial data on the use of magrolimab plus azacitidine for patients with TP53-mutated AML.
EP. 14: ENHANCE-3 Trial of Magrolimab in Combination with Venetoclax and Azacitidine in AML
Closing out their discussion, Drs Hetty Carraway and Eytan M. Stein highlight an ongoing clinical trial investigating a triplet therapy for AML.
2 Clarke Drive Cranbury, NJ 08512